| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 23.05.
| Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting | | 54 | PR Newswire |
| WASHINGTON, May 22, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system...
Mehr lesen zu:
Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting | |
| 18.05.
| Vanda Pharmaceuticals Looks to Continue to Trade Below its Annual-Low Share Price Today | | 1 | SmarTrend |
| 17.05.
| Vanda Pharmaceuticals: The Losing Streak Continues | | 1 | SmarTrend |
| 09.05.
| Vanda Pharmaceuticals Inc. - 10-Q, Quarterly Report | | 1 | SEC Filings |
| 08.05.
| Vanda Pharmaceuticals Reports First Quarter 2012 Results | | 8 | PR Newswire |
| WASHINGTON, May 8, 2012 /PRNewswire/ --Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment...
Mehr lesen zu:
Vanda Pharmaceuticals Reports First Quarter 2012 Results | |
| 18.04.
| Vanda Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012 | | 21 | PR Newswire |
| WASHINGTON, April 18, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous...
Mehr lesen zu:
Vanda Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012 | |
| 16.04.
| UPDATE 1-Vanda buys Lilly's experimental drug | | 4 | Reuters.com |
| 16.04.
| Vanda Pharma Acquires Rights To NK-1 Receptor Antagonist From Eli Lilly | | 43 | AFX News |
| INDIANAPOLIS (dpa-AFX) - Vanda Pharmaceuticals Inc. (VNDA) said it has
acquired an exclusive world-wide license from Eli Lilly and Co. (LLY) to develop
and commercialize a small molecule...
Mehr lesen zu:
Vanda Pharma Acquires Rights To NK-1 Receptor Antagonist From Eli Lilly | |
| 16.04.
| Vanda Pharmaceuticals (VNDA) Gets NK-1R License Agreement with Lilly (LLY) | | - | StreetInsider.com |
| 16.04.
| Vanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist from Eli Lilly and Company | | 13 | PR Newswire |
| WASHINGTON, April 16, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central...
Mehr lesen zu:
Vanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist from Eli Lilly and Company | |
| 09.03.
| Vanda Pharmaceuticals Inc. - 10-K, Annual Report | | 2 | SEC Filings |
| 24.02.
| Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences | | 48 | PR Newswire |
| ROCKVILLE, Md., Feb. 23, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment...
Mehr lesen zu:
Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences | |
| 14.02.
| Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results | | 11 | PR Newswire |
| ROCKVILLE, Md., Feb. 14, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment...
Mehr lesen zu:
Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results | |
| 19.01.
| Vanda Pharmaceuticals to Announce Fourth Quarter 2011 Financial Results on February 14, 2012 | | 45 | PR Newswire |
| ROCKVILLE, Md., Jan. 18, 2012 /PRNewswire/ --Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central...
Mehr lesen zu:
Vanda Pharmaceuticals to Announce Fourth Quarter 2011 Financial Results on February 14, 2012 | |
| 13.12.
| Vanda Pharmaceuticals (VNDA) Announces Exclusive License Agreement with Megapharm for Commercialization of Fanapt in Israel | | 1 | StreetInsider.com |
| 13.12.
| Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt' in Israel | | 8 | PR Newswire |
| ROCKVILLE, Md., Dec. 13, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...
Mehr lesen zu:
Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt' in Israel | |
